← boothcheck

Is CI overvalued?

boothcheck doesn't label CI overvalued or undervalued, and it doesn't publish a fair value. It shows what the price assumes instead. The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet. The more the price assumes beyond what The Cigna Group has actually delivered, the more has to go right to justify it. Whether that bar is too high is your call, and the full bull and bear cases are in the report.

Derived from The Cigna Group's SEC EDGAR filings via a reverse-DCF inversion. Last analyzed June 27, 2026.

Implied growth
For about
Margin needed
Margin today
Price vs asset value1.04x
Price vs earnings power0.88x
Price vs peer multiples0.41x
Price vs forward growth0.68x
Read the full CI report →
Get boothcheck's read on what CI's price is betting on, in your inbox when it moves. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.